ZLN024

Confirm delete?

ZLN024

Zoom

Cat No: 21644

Biochemicals - Small Molecule Activators

ZLN024 is an allosteric activator of AMP-activated protein kinase (AMPK) heterotrimers (EC50s = 0.42 and 0.95 µM for α1β1γ1 and α2β1γ1, respectively).{33850} Activation of AMPK by ZLN024 requires phosphorylation of AMPK on Thr172, and ZLN024 protects ...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

2-[[2-(2-bromo-4-methylphenoxy)ethyl]thio]-pyrimidine

Correlated keywords:

1883548-91-1 ZLN-024 24 a1b1g1 a2b1g1 a1 b1 g1 a2 2Ca PP-2Ca PP2Ca PP2C? thr-172 threonine L-6

Product Overview:
ZLN024 is an allosteric activator of AMP-activated protein kinase (AMPK) heterotrimers (EC50s = 0.42 and 0.95 µM for α1β1γ1 and α2β1γ1, respectively).{33850} Activation of AMPK by ZLN024 requires phosphorylation of AMPK on Thr172, and ZLN024 protects Thr172 from dephosphorylation by protein phosphatase 2Cα.{33850} ZLN024 stimulates glucose uptake and fatty acid oxidation in L6 myotubes. In primary hepatocytes, ZLN024 decreases fatty acid synthesis and glucose output.{33850} ZLN024 reduces liver triacylglycerol and total cholesterol content and improves glucose tolerance in db/db mice.{33850}

Size	5 mg
Shipping	dry ice
CAS Number	723249-01-2
Molecular Formula	C₁₃H₁₃BrN₂OS
SMILES	CC1=CC(Br)=C(OCCSC2=NC=CC=N2)C=C1
Molecular Weight	325,2
Formulation	A crystalline solid
Purity	≥98%
Custom Code	2903.99
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.